Biohit Oyj - Company Announcement

BIOHIT OYJ TO ISSUE A CONVERTIBLE BOND

BIOHIT OYJ STOCK EXCHANGE RELEASE ON 3 AUGUST 2010 AT 01:00 PM 

BIOHIT OYJ TO ISSUE A CONVERTIBLE BOND                                          

Authorized by the Annual General Meeting, the Board of Directors of Biohit Oyj  
has decided today to issue a convertible bond targeted at institutional         
investors in Finland. 

Deviating from the shareholders' pre-emptive subscription right, the bond will
be offered for subscription to shareholders chosen by the Board of Directors.
The bond has a value of EUR 4.05 million and a five-year maturity. The fixed
coupon rate of the bond is 6.5%. The bond is set to be issued on 28 October
2010 and will not become available for public trading. 
This new bond will replace Biohit Oyj's earlier convertible bond of the same    
size, which is due to mature in October 2010. The issue is part of a set of     
measures aimed at optimising the company's long-term financing plan. On this    
basis, the company takes the view that there are substantial financial reasons  
for deviating from the shareholders' pre-emptive subscription right.            

The issue will be chiefly organised by Pohjola Corporate Finance Oy.            

Jussi Heiniö                                                                    
President & CEO                                                                 
Biohit Oyj                                                                 


Further information:                                                            
Jussi Heiniö, President & CEO                                                   
Tel: +358-9-773 861                                                             
Email: jussi.heinio@biohit.com                                                  

Distribution:                                                                   
NASDAQ OMX Helsinki Oy                                                          
Central storage facility (www.oam.fi)                                           
Press                                                                           
www.biohit.com                                                                  


About Biohit Oyj                                                                

Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on   
the global market. Biohit's operations are based on a goal-oriented and         
long-term innovation and patenting strategy.                                    
Biohit works with scientific communities to produce new technologies, products  
and services based on research results and innovations that can be used to      
develop safe and cost-effective liquid handling solutions for laboratory work as
well as diagnostic tests for the early detection and prevention of diseases of  
the gastrointestinal tract.                                                     

Biohit has two business segments: liquid handling and diagnostics. Liquid       
handling products include electronic and mechanical pipettes, disposable tips as
well as pipette maintenance and calibration services for research institutions, 
healthcare and industrial laboratories.                                         

The diagnostics business comprises products and analysis systems for the early  
diagnosis of gastrointestinal diseases, such as the blood-sample based          
GastroPanel examinations for the diagnosis of stomach illnesses and associated  
risks, quick tests for the diagnosis of lactose intolerance and H. pylori       
infection in connection with gastroscopy, and the ColonView examination for the 
early detection of intestinal bleeding that indicates a risk of colorectal      
cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic    
stomachs.                                                                       

The Biohit Group employs around 390 people. The company is headquartered in     
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,     
India, China, Japan and the USA, as well as a representative office in          
Singapore. Additionally, Biohit's products are sold by approximately 450        
distributors in 70 countries.                                                   

Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small         
cap/Healthcare since 1999.                                                      

Read more at www.biohit.com